Clinical Trial Update: Momelotinib in VEXAS Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating momelotinib for VEXAS syndrome is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Vexas Syndrome

Drugs mentioned

• Momelotinib (momelotinib)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: VEXAS Syndome, Myelo Dysplastic Syndrome | Phase 2 | Status: RECRUITING